PARIS & DALLAS, May 18 — Tulyp Medical, a Paris-based medical device company developing an intelligent pressure-driven perfusion system, today announced the appointment of Steve Motes as Chief Executive Officer. The appointment follows positive results from the company’s first-in-human study.
Steve joins Tulyp with more than 30 years of experience in the medical device industry, primarily focused on cardiovascular technologies. He has held leadership roles at Draeger, Medtronic (formerly Somanetics), Edwards Lifesciences, and Abbott. At Abbott, he contributed to the launch of the HeartMate 3 LVAD system and played a key role in expanding the company’s ECMO business. More recently, he has served as CEO of several early-stage companies, including those in the MCS space.
“I am thrilled to join Tulyp at this pivotal stage,” said Steve. “Tulyp is advancing a fundamentally different approach to perfusion that aligns more closely with how the body actually regulates oxygen delivery. In procedures where perfusion is compromised, maintaining pressure is critical to preserving tissue viability. The early data suggest this approach could meaningfully reduce complications and expand the standard of care in vascular interventions. I look forward to advancing this therapy toward broader clinical adoption and improved patient outcomes.”
“We are excited to welcome Steve to Tulyp,” said Mano Iyer, Partner at Sofinnova Partners. “He brings not only his wealth of experience and deep network in the MCS world, but also a proven ability to build companies in complex clinical markets. His appointment reinforces our conviction in Tulyp’s differentiated approach—addressing a fundamental limitation of flow-based perfusion by focusing on pressure as the key driver of tissue oxygenation. As I transition from CEO to the Board, which is the natural and anticipated course of events within the unique Sofinnova MD Start accelerator model, I look forward to continuing to support the company’s strategic direction as we advance this technology toward broader clinical adoption and improved patient outcomes.”
Tulyp was founded by an experienced team of cardiologists, engineers, and entrepreneurs, including Tim Lenihan (Co-founder and COO), Dr. Navin Kapur, and Dr. Richard Karas, who continue to advise the company. The team previously co-founded preCARDIA, a Sofinnova Partners’ MD Start company, acquired by Abiomed (a Johnson & Johnson company) in 2021, following the successful development of a device for treating acute decompensated heart failure.